Innate Immunotherapeutics

Innate Immunotherapeutics is a medical biotechnology company that has offices in Sydney (Australia) and Auckland (New Zealand).

The Company has designed and manufactured a unique immunomodulator microparticle technology and this technology can be used to induce the human immune system to fight certain cancers and infections, or modulate certain immune mechanisms implicated in autoimmune diseases such as Multiple Sclerosis. The same technology can be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.

The microparticle at the core of its developed technology provides a delivery system for a suite of known and novel immune system triggers or modulators. By attaching selected modulators to the microparticle, these triggers can be delivered reliably to specific cells of the immune system.

The first drug candidate that was developed using its technology, MIS416, combines well-described immunostimulatory ligands or triggers - NOD2 and TLR9. Its MIS416, has demonstrated efficacy and safety in different diseases or injury models. Due to the significant degree of unmet medical need, Secondary Progressive Multiple Sclerosis has been selected as the initial clinical target for MIS416.